DBV Technologies (NASDAQ:DBVT – Get Free Report)‘s stock had its “market outperform” rating reissued by JMP Securities in a note issued to investors on Tuesday, Benzinga reports. They currently have a $5.00 price target on the stock.
Several other brokerages also recently weighed in on DBVT. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com assumed coverage on shares of DBV Technologies in a research report on Thursday, September 19th. They set a “hold” rating on the stock.
Read Our Latest Stock Analysis on DBV Technologies
DBV Technologies Trading Up 3.0 %
DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. During the same quarter last year, the company posted ($0.26) EPS. On average, equities analysts expect that DBV Technologies will post -1.43 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
- Five stocks we like better than DBV Technologies
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
- How to Invest in Blue Chip Stocks
- Is Aggressive Trading Your Path to Quick Profits?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Williams Sonoma Stock Could Be Ripe for a Short at Current Levels
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.